Larimar Therapeutics, Inc.
LRMR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $185,041 | $137,523 | $246,948 |
| - Cash | $90,140 | $20,587 | $21,126 | $33,218 |
| + Debt | $3,196 | $4,614 | $4,866 | $5,117 |
| Enterprise Value | – | $169,068 | $121,263 | $218,847 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$47,624 | -$27,705 | -$31,100 | -$31,216 |
| % Margin | – | – | – | – |
| Net Income | -$47,712 | -$26,182 | -$29,281 | -$28,824 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.61 | -0.41 | -0.46 | -0.45 |
| % Growth | -48.8% | 10.9% | -2.2% | – |
| Operating Cash Flow | -$28,753 | -$19,381 | -$26,540 | -$21,815 |
| Capital Expenditures | -$23 | -$19 | -$49 | -$179 |
| Free Cash Flow | -$28,776 | -$19,400 | -$26,589 | -$21,994 |